Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
dirucotide · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| Dirucotide | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| dirucotide | DRUG | 500mg, intravenous, every 6 months for 15 months |
| placebo | DRUG | intravenous, once every six months for 15 months |
Inclusion Criteria: 1. Male or female subjects, 18-50 years of age 2. Relapsing-remitting multiple sclerosis (RRMS) according to "Diagnostic criteria for multiple sclerosis: 2005 revisions to the McDonald Criteria" (Annals of Neurology 58: 840-846) 3. At least 2 years history of MS before trial ent...
Dirucotide is an investigational small molecule being studied for the treatment of relapsing remitting multiple sclerosis and secondary progressive multiple sclerosis. It is in Phase 2 clinical development and has not been approved by regulatory authorities.
Dirucotide is being developed by Eli Lilly and Company, a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol LLY. The drug is currently in Phase 2 clinical trials for multiple sclerosis indications.
Dirucotide is in Phase 2 clinical development. It has completed two Phase 2 trials, one in secondary progressive multiple sclerosis and one in relapsing remitting multiple sclerosis. The drug remains investigational and has not received regulatory approval.
Dirucotide has been studied in two completed Phase 2 trials. NCT00869726 enrolled 596 participants with secondary progressive multiple sclerosis across multiple countries. NCT00869986 enrolled 218 participants with relapsing remitting multiple sclerosis in Eastern European countries. Both trials were randomized, double-blind, and placebo-controlled.
Dirucotide is not FDA approved. It is an investigational drug that has completed Phase 2 clinical trials for multiple sclerosis. The drug is still in clinical development and has not been authorized for commercial use.